News Focus
News Focus
Replies to #97407 on Biotech Values
icon url

genisi

06/18/10 3:22 PM

#97433 RE: DewDiligence #97407

I expect that Gleevec will remain the tyrosine kinase inhibitor of choicee in first-line CML until data from Tasigna and or Sprycel will show superiority in OS.